P311 A novel interaction between COMP and granulin-epithrin precursor (GEP): Poterntial effects on musculoskeletal tumors growth  by unknown
$154 Poster Presentat ions 
induced a marked increase of MTT values compared to control 
culture. Time course experiments performed with chondrocytes 
cultivated in 30% platelet poor plasma (PPP) or in 30% PRP 
showed that PRP promoted an increase of MTT values that was 
observed for the entire 12 day testing period. 
In PRP gel, cell bodies and pericellular matrix were stained more 
strongly with alcian blue compared with that in PPP gel. Like- 
wise, immunoreactivity to the anti-type II collagen antibodies was 
shown more certainly in PRP gel. Histochemical and immuno- 
histochemical examinations demonstrated that cultivated chon- 
drocytes can easily lose their phenotype ven in passage 1 cells, 
however PRP enhances redifferentiation ofdedifferentiated chon- 
drocytes. 
Conclusion: 30% PRP promotes human chondrocyte prolifer- 
ation. Cells expanded with 30% PRP can express chondrocyte 
phenotype. It is suggested that PRP gel provides an invaluable 
source of growth factors for human chondrocyte proliferation and 
redifferentiation, and could serve as a scaffold for autologous 
chondrocyte implantation that has potential availability for repair 
of osteoarthritis with chondral defects. 
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Study aims: Granulin-epithelin precursor (GEP) was identified as 
a COMP-binding protein in a functional genetic screen. GEP is a 
secreted growth facotor. It contributes to tumorigenesis in diverse 
cancers. The aim of this study was to characterize the interaction 
between GEP and COMP and to investigate their potential as 
therapeutic targets in musculoskeletal tumors. 
Methods: Yeast two hybrid (Y2H) Library Screen. Functional do- 
mains of COMP were used as bait to screen rat brain pPC86 
cDNA library. In VitroBinding Assay - Glutathione-Sepharose 
beads preincubated with either GST or GST-EGF domain of 
COMP were incubated with purified His-tagged GEP. Bound pro- 
teins were detected with anti-His antibodies. Proliferation Assay 
- rat chondrosarcoma cells (RCS) were transfected with empty 
vector, construct encoding GEP and constructs encoding GEP 
and COMP respectively and selected with G418. Cell prolifera- 
tion was assayed by seeding lx105 cells into 6-well plates. Cells 
were harvested and viable cells were counted. 
Results: Isolation of GEP as a COMP binding partner. To better 
understand the biological functions of COME we performed Y2H 
screen. Briefly, a Y2H rat cDNA library was screened with the 
construct encoding the EGF-like repeats of COME We screened 
approximately 2.5 million clones and identified 12 positive clones. 
Two positive clones among them encoded two N-terminal trun- 
cated mutants (a.a. 228-588; a.a.334-588) of GEP (Accession 
#NM_017113.1). 
COMP directly binds to GEP - To verity the interaction between 
COMP and GEP which was first identified in yeast, a GST pull- 
down assay was performed to test whether EGF-like domain of 
COMP binds to the C-terminal of GEP (a.a.228-588) in vitro. 
GST did not pull down GEP protein, whereas GST-EGF efficiently 
pulled down GEP protein, indicating binding of COMP to GEP in 
vitro. 
COMP enhances the GEP-mediated stimulation of chondrosar- 
coma cellproliferation - Overexpression of COMP alone produce 
negligible effects on tumor cell growth; whereas overexpression 
of GEP resulted in a clear increase in cell proliferation by 43% in 
day 3 and robust stimulation was observed in day 4 (1.8 fold) and 
day 5 (3.5 folds). Intriguingly this GEP-mediated stimulation was 
further enhanced by co-expression of COMP. The enhancement 
was observed since day 2 (2.3 folds) and remained significant 
with slightly going down (2.1 folds in day 3, 1.7 folds in day 4 and 
1.5 folds in day 5 respectively). 
Conclusion: We reported a novel interaction between a muscu- 
Ioskeletal tissues-specific extracellular matrix COMP protein and 
a GEP growth factor and the enhancement of GEP-stimulated 
chondrosarcoma growth by COME Since GEP was found to pro- 
mote the growth, invasion and metastasis of several tumors, our 
findings demonstrate that COMP may function as an important 
mediator of musculoskeletal tumors via associating with GEP, 
presenting GEP to its membrane receptor and regulating GEP- 
mediated signal transduction and gene regulation pathways. 
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Although OA is not considered an inflammatory arthropathy, it is 
now clear that inflammatory modulators are prominent players in 
pathogenesis of the disease. Overproduction of the immunomod- 
ulator prostaglandin E2 (PGE2) and of the rate-limiting enzyme 
involved in its biosynthesis, cyclooxygenase-2 (COX-2), by OA 
and RA chondrocytes and human synovial fibroblasts (HSFs) 
have made this enzyme the subject of intense interest. While 
an impressive number of regulatory mechanisms implicated in 
COX-2 gene expression are now known, the mechanisms regu- 
lating COX-2 catalytic activity are still not fully understood. We 
have uncovered a novel control mechanism involving limited pro- 
teolysis of the COX-2 protein that regulates intrinsic cyclooxy- 
genase/peroxidase activities and ultimately the biosynthesis of 
PGE2. IL-11~ stimulation of human synovial fibroblasts (HSFs), 
chondrocytes and macrophages induced the synthesis of COX- 
2 protein and its coincident proteolysis into a series of stable, 
distinct immunoreactive fragments (i.e., 66, 42-44, 34-36 and 28 
kDa) that accumulated in a time-dependent manner. The induc- 
tion of PGE2 synthesis (i.e., COX-2 activity) in HSFs coincided 
with the start of COX-2 fragmentation. Regression analysis con- 
firmed a direct linear correlation (R2=0.91) between PGE2 se- 
cretion and the timing and degree of COX-2 proteolysis in IL-11~- 
treated HSFs, as well as cells treated with other arthropathologi- 
cally relevant pro-inflammatory c tokines (i.e., TNF-alpha, IL-17). 
Cleavage positions within COX-2 were confined to the catalytic 
domain as confirmed by mass-spectrometry (MALDI-TOF). Phar- 
macological inhibition of induced COX-2 activity by a variety of 
non-selective and COX-2-specific NSAIDs abrogated proteolysis. 
NSAID-mediated inhibition of proteolysis was not mechanistically 
related to direct enzymatic inactivation of COX-2, as shown by 
the reduction in COX-2 cleavage and PGE2 synthesis by (R)- 
flurbiprofen, which does not inhibit COX-2 and is not efficiently 
isomerized to the active (S)-flurbiprofen. These results pointed 
to the involvement of NSAID-sensitive proteolytic enzymes in the 
COX-2 fragmentation process, a hypothesis upported by the cor- 
related reduction in COX-2 cleavage and PGE2 synthesis by both 
g-secretase and cysteine/calpain protease inhibitors. Our results 
suggest that nascent COX-2 is initially in an enzymatically latent 
form and must be activated by limited proteolysis for full biosyn- 
thetic activity. 
